An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. J of Skin 2020, 4 (5), s27. https://doi.org/10.25251/skin.4.supp.27.